Astellas Oncology at ASCO 2021

Over the last decade there have been tremendous advances in the field of oncology, but there are still patients that need more options for hard-to-treat cancers. During the 2021 American Society of Oncology (ASCO) Annual Meeting, Astellas Oncology will present data across our portfolio of therapies that help to advance our commitment to changing the course for patients with bladder, acute myeloid leukemia (AML), prostate and gastric gastroesophageal junction (GEJ) cancers.

Learn more about our portfolio, as well as the ambitious thinking and spirited collaboration that drives our work at www.astellasoncology.com. 

 

A Message From Astellas Oncology Leadership

 

Our ASCO Abstracts and Press Releases

Astellas at ASCO 2021

Presentation Overview

 

May 19, 2021Astellas and Seagen Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy

May 17, 2021Astellas to Present Data from Expanding Oncology Portfolio During the 2021 ASCO Annual Meeting

 

The Role of the Caregiver

Caregivers often play the essential role of supporter throughout the emotional rollercoaster of a cancer diagnosis, accompanying those with cancer through treatment and beyond. Find out just how powerful this role can be:

 

 

Our Thank You To Oncology Nurses

074-0426-PM 05/21

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

 

For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

 

Astellas on Twitter
Download Fact Sheet

Download Fact Sheet

Sustainability

Sustainability

Investors

Investors

Explore U.S. Products

Explore U.S. Products